nach oben

Erschienen in:

09.11.2019 | PHASE I STUDIES

A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study

verfasst von: Sarah Lapointe, Warren Mason, Mary MacNeil, Craig Harlos, Roger Tsang, Joana Sederias, H. Artee Luchman, Samuel Weiss, John P. Rossiter, Dongsheng Tu, Lesley Seymour, Martin Smoragiewicz

Erschienen in: Investigational New Drugs | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Summary

The PI3K/AKT/mTOR pathway activation plays a central role in glioblastoma multiforme (GBM) development and progression, and in resistance to anti-cancer therapies. Inhibition of the PI3K pathway has been shown to sensitize cultured glioma cells and tumor xenografts to the effects of temozolomide (TMZ) and radiation. Vistusertib is an oral inhibitor of mTORC1/2 complexes. The primary objective of this Canadian Cancer Trials Group phase I study was to determine the recommended phase II dose (RP2D) of vistusertib in patients with GBM receiving TMZ at first progression following primary treatment. Vistusertib was administered at a starting dose of 100 mg bid 2 days on/5 days off weekly with TMZ 150 mg/m² daily for 5 days/28-days cycle. Dose escalation was according to a 3 + 3 design. Secondary objectives included assessment of vistusertib safety and toxicity profile, and preliminary efficacy. 15 patients were enrolled in the study (median age 66 (range 51–77), females 8). Vistusertib 125 mg BID in combination with TMZ 150 mg/m² daily for 5 days was well tolerated. Vistusertib treatment-related adverse events were generally grade 1–2, with the most frequently reported being fatigue, gastrointestinal symptoms, and rash. Of 13 response evaluable patients, 1 patient (8%) had a partial response ongoing at 7.6 months of follow-up, and 5 patients had stable disease (38%) as best response (median duration 9.6 months, range 3.7-not yet reached). Six-month progression-free survival (PFS) rate was 26.6%. Combination of vistusertib with TMZ in GBM patients at first recurrence demonstrated a favorable safety profile at the tested dose levels.

Ostrom QT, Gittleman H, Truitt G et al (2018) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol 20:iv1–iv86. https://doi.org/10.1093/neuonc/noy131 CrossRefPubMedPubMedCentral

Stupp R, Hegi ME, Gilbert MR, Chakravarti A (2007) Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25:4127–4136. https://doi.org/10.1200/JCO.2007.11.8554 CrossRefPubMed

Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study : 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. https://doi.org/10.1016/S1470-2045(09)70025-7 CrossRefPubMed

Wick W, Gorlia T, Bendszus M et al (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377:1954–1963. https://doi.org/10.1056/NEJMoa1707358 CrossRefPubMed

Schiff D, Jaeckle KA, Anderson SK et al (2018) Phase 1 / 2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma : north central cancer treatment group study / alliance N0572. Cancer 1455–1463. https://doi.org/10.1002/cncr.31219

Mecca C, Giambanco I, Donato R, Arcuri C (2018) Targeting mTOR in glioblastoma: rationale and preclinical/clinical evidence. Dis Markers 2018:1–10. https://doi.org/10.1155/2018/9230479 CrossRef

Zhao H, Wang J, Shao W et al (2017) Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer 16:100. https://doi.org/10.1186/s12943-017-0670-3 CrossRefPubMedPubMedCentral

Bahmad HF, Mouhieddine TH, Chalhoub RM et al (2018) The Akt / mTOR pathway in cancer stem / progenitor cells is a potential therapeutic target for glioblastoma and neuroblastoma. Oncotarget 9:33549–33561. https://doi.org/10.18632/oncotarget.26088 CrossRefPubMedPubMedCentral

Zhavoronkov A (2015) Inhibitors of mTOR in aging and cancer. Oncotarget 6:45011. https://doi.org/10.4161/cbt.22859 CrossRef

10.

Choi EJ, Cho BJ, Lee DJ et al (2014) Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases. BMC Cancer 14:1–12. https://doi.org/10.1186/1471-2407-14-17 CrossRef

11.

Choe G, Horvath S, Cloughesy TF et al (2003) Analysis of the PI3K signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742–2746PubMed

12.

Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28:1075–1083. https://doi.org/10.1200/JCO.2009.25.3641 CrossRefPubMedPubMedCentral

13.

Network TCGAR (2008) Comprehensive genomic characterization defines human gliblastoma genes and core pathways. Nature 455:1061–1068. https://doi.org/10.1038/nature07385.Comprehensive CrossRef

14.

David A, Fruman CR (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13:140–156. https://doi.org/10.1038/mp.2011.182.doi CrossRef

15.

Li X, Wu C, Chen N et al (2016) PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget 7:33440–33450. https://doi.org/10.18632/oncotarget.7961 CrossRefPubMedPubMedCentral

16.

Luchman HA, Stechishin ODM, Nguyen SA et al (2014) Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Clin Cancer Res 20:5756–5767. https://doi.org/10.1158/1078-0432.CCR-13-3389 CrossRefPubMed

17.

Sasaki H, Zlatescu MC, Betensky RA et al (2001) PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 159:359–367. https://doi.org/10.1016/S0002-9440(10)61702-6 CrossRefPubMedPubMedCentral

18.

Sano T, Lin H, Chen X et al (1999) Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59:1820–1824PubMed

19.

Smith JS, Tachibana I, Passe SM et al (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246–1256

20.

Nakamura JL, Garcia E, Pieper RO (2008) S6K1 plays a key role in glial transformation. Cancer Res 68:6516–6523. https://doi.org/10.1158/0008-5472.CAN-07-6188 CrossRefPubMedPubMedCentral

21.

Chinnaiyan P, Won M, Wen PY et al (2018) A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG oncology RTOG 0913. Neuro-Oncology 20:666–673. https://doi.org/10.1093/neuonc/nox209 CrossRefPubMed

22.

Wen PY, Chang SM, Lamborn KR et al (2014) Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: north American brain tumor consortium trial 04-02. Neuro-Oncology 16:567–578. https://doi.org/10.1093/neuonc/not247 CrossRefPubMedPubMedCentral

23.

Reardon DA, Desjardins A, Vredenburgh JJ et al (2010) Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neuro-Oncol 96:219–230. https://doi.org/10.1007/s11060-009-9950-0 CrossRef

24.

Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Karen F, Ian Robins H, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Janet Dancey MDP (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investig New Drugs 23:357–361. https://doi.org/10.1007/s11523-018-0605-y CrossRef

25.

Wick W, Gorlia T, Bady P et al (2016) Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-15-3153

26.

Mellinghoff IK, Cloughesy TF, Mischel PS (2007) PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 13:378–381. https://doi.org/10.1158/1078-0432.CCR-06-1992 CrossRefPubMed

27.

O’Brien NA, Browne BC, Chow L et al (2010) Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 9:1489–1502. https://doi.org/10.1158/1535-7163.mct-09-1171 CrossRefPubMed

28.

Priulla M, Calastretti A, Bruno P, Amalia A, Paradiso A, Canti G, Nicolin A (2007) Preferential Chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate 67:782–789. https://doi.org/10.1002/pros CrossRefPubMed

29.

Sequist LV, Waltman BA, Dias-santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:1–27. https://doi.org/10.1126/scitranslmed.3002003.Genotypic CrossRef

30.

Momota H, Nerio E, Holland EC (2005) Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 65:7429–7435. https://doi.org/10.1158/0008-5472.CAN-05-1042 CrossRefPubMed

31.

Jiang Z, Pore N, Cerniglia GJ et al (2007) Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res 67:4467–4473. https://doi.org/10.1158/0008-5472.CAN-06-3398 CrossRefPubMed

32.

Pike KG, Malagu K, Hummersone MG et al (2013) Bioorganic & medicinal chemistry letters optimization of potent and selective dual mTORC1 and mTORC2 inhibitors : the discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett 23:1212–1216. https://doi.org/10.1016/j.bmcl.2013.01.019 CrossRefPubMed

33.

Wen PY, Macdonald DR, Reardon DA et al (2010) Updated Response Assessment Criteria for High-Grade Gliomas : Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 28. https://doi.org/10.1200/JCO.2009.26.3541

34.

Wen PY, Omuro A, Ahluwalia MS et al (2015) Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro-Oncology 17:1275–1283. https://doi.org/10.1093/neuonc/nov083 CrossRefPubMedPubMedCentral

35.

Stupp R, Mason WP, Van Den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330 CrossRef

36.

Wick W, Platten M, Weller M (2009) New (alternative) temozolomide regimens for the treatment of glioma. Neuro-Oncology 11:69–79. https://doi.org/10.1215/15228517-2008-078 CrossRefPubMedPubMedCentral

37.

Rodon J, Dienstmann R, Serra V, Tabernero J (2013) Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 10:143–153. https://doi.org/10.1038/nrclinonc.2013.10 CrossRefPubMed

38.

Schmid P, Zaiss M, Harper-Wynne C et al (2018) MANTA - a randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. Cancer Res 78:GS2-07-GS2-07. https://doi.org/10.1158/1538-7445.SABCS17-GS2-07

39.

Powles T, Wheater M, Din O et al (2016) A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer. Eur Urol 69:450–456. https://doi.org/10.1016/j.eururo.2015.08.035 CrossRefPubMed

Titel: A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study
verfasst von: Sarah Lapointe
Warren Mason
Mary MacNeil
Craig Harlos
Roger Tsang
Joana Sederias
H. Artee Luchman
Samuel Weiss
John P. Rossiter
Dongsheng Tu
Lesley Seymour
Martin Smoragiewicz
Publikationsdatum: 09.11.2019
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 4/2020
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-019-00875-4

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study

Summary

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors

Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells

Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)

Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors

Identification of HGF as a novel target of miR-15a/16/195 in gastric cancer

Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer – the role of STAT3 and p21

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie